EANS-News: Epigenomics AG: Study Shows Patient Preference for Blood Based
Colorectal Cancer Screening
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information/New Products/molecular diagnostics
Berlin, Germany, and Seattle, WA, U.S.A., March 6, 2012 (euro adhoc) -
Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer
molecular diagnostics company, today announced that results of a survey on
colorectal cancer (CRC) screening preferences conducted by Jennifer Taber et al.
(Department of Psychology University of Utah, Huntsman Cancer Institute, ARUP
Laboratories) were presented at the American Society for Preventive Oncology
2012 Annual Meeting in Washington, DC on March 5, 2012.
The study assessed the attitudes and preferences of 100 participants eligible
for CRC screening of which 44% were previously unscreened, with respect to
screening by FOBT, sigmoidoscopy, colonoscopy or Septin9 blood testing. In this
focus group study, participants completed a survey after a 90 minute moderated
discussion about the procedure, cost and accuracy of all tests.
The survey indicated that given the performance of the ARUP Septin9 test (90%
sensitive, 89% specific; Warren et al. 2011) and its cost of approximately USD
180, two thirds of previously unscreened subjects would prefer a Septin9 blood
test to other screening methods. Among the positive aspects of the test,
participants noted its convenience (62%), cost (52%) and accuracy (55%). Among
the negative factors of the test, participants mentioned the inability to detect
precancerous polyps (6%) and lack of insurance coverage (6%).
Noel Doheny, CEO of Epigenomics' US subsidiary and member of the Epigenomics
Senior Management Team noted: "The study demonstrates that the convenience of a
blood based test should lead to a greater acceptance and thus a higher
compliance to colorectal cancer screening. It underlines the value that
blood-based Septin9 tests can potentially bring as alternative for the detection
of colorectal cancer".
Karen Heichman, Ph.D., VP Oncology Technology Development & Licensing, ARUP
Laboratories added: "ARUP is proud to provide a non-invasive blood based
approach that people can use for the early detection of colorectal cancer".
- Ends -
Further Information
Contact Epigenomics AG
Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.comwww.epigenomics.com
About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing
and commercializing a pipeline of proprietary products for cancer. The Company's
products enable doctors to diagnose cancer earlier and more accurately, leading
to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is
a blood-based test for the early detection of colorectal cancer, which is
currently marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple partnerships with
leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations in Europe
and the U.S.A.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise.
The information contained in this communication does not constitute nor imply an
offer to sell or transfer any product, and no product based on this technology
is currently available for sale by Epigenomics in the United States or Canada.
The analytical and clinical performance characteristics of any Epigenomics
product based on this technology which may be sold at some future time in the
U.S. have not been established.
Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English